Bio-Rad Laboratories, Inc. (NYSE:BIO) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Thursday.

According to Zacks, “Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company’s products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California. “

Other equities research analysts also recently issued reports about the company. BidaskClub raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. Deutsche Bank AG raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating and decreased their target price for the stock from $220.00 to $195.00 in a research report on Wednesday, June 28th. TheStreet downgraded Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. Jefferies Group LLC reissued a “buy” rating and set a $275.00 target price on shares of Bio-Rad Laboratories in a research report on Friday, July 14th. Finally, Wells Fargo & Company began coverage on Bio-Rad Laboratories in a research report on Thursday, July 13th. They set an “outperform” rating and a $250.00 target price on the stock. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $228.80.

Bio-Rad Laboratories (NYSE:BIO) traded down 1.80% on Thursday, hitting $215.00. The company had a trading volume of 195,388 shares. Bio-Rad Laboratories has a 12-month low of $147.68 and a 12-month high of $242.79. The stock has a market cap of $6.37 billion, a P/E ratio of 424.90 and a beta of 0.91. The firm’s 50 day moving average price is $229.69 and its 200 day moving average price is $212.16.

COPYRIGHT VIOLATION WARNING: “Bio-Rad Laboratories, Inc. (NYSE:BIO) Rating Lowered to Sell at Zacks Investment Research” was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.dailypolitical.com/2017/08/10/bio-rad-laboratories-inc-nysebio-rating-lowered-to-sell-at-zacks-investment-research.html.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Riverhead Capital Management LLC boosted its position in shares of Bio-Rad Laboratories by 79.9% in the second quarter. Riverhead Capital Management LLC now owns 1,799 shares of the medical research company’s stock worth $407,000 after buying an additional 799 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Bio-Rad Laboratories by 93.1% in the second quarter. Wells Fargo & Company MN now owns 523,876 shares of the medical research company’s stock worth $118,557,000 after buying an additional 252,643 shares in the last quarter. TimesSquare Capital Management LLC boosted its position in shares of Bio-Rad Laboratories by 1.6% in the second quarter. TimesSquare Capital Management LLC now owns 621,650 shares of the medical research company’s stock worth $140,686,000 after buying an additional 9,950 shares in the last quarter. Old Mutual Global Investors UK Ltd. boosted its position in shares of Bio-Rad Laboratories by 100.0% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 3,200 shares of the medical research company’s stock worth $724,000 after buying an additional 1,600 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of Bio-Rad Laboratories by 53.2% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 33,494 shares of the medical research company’s stock worth $7,580,000 after buying an additional 11,635 shares in the last quarter. Hedge funds and other institutional investors own 63.73% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Get a free copy of the Zacks research report on Bio-Rad Laboratories (BIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.